posted
Keep an I on this one, they had a patent approved a couple weeks ago. I believe MM's shorted the pizz out of it and have now held it down long enough to cover. Heard that 41% is owned by insiders. Might take-off, way undervalued IMHO!
Posts: 410 | Registered: Jan 2006
| IP: Logged |
posted
I like the way this is holding here just under resistance. GSCO has been on the top of the bid constantly for the past several weeks and is now as well. He's buying up everything for a reason IMO.
Posts: 410 | Registered: Jan 2006
| IP: Logged |
Advanced Viral Research (ADVR) is Granted US Patent for Rheumatoid Arthritis Business Wire - July 17, 2006 12:26 PM ET
Related Quotes Symbol Last Chg ADVR Trade 0.068 0.00 Quotes delayed at least 15 minutes
Advanced Viral Research Corp. (OTC Bulletin Board: ADVR) a bio-pharmaceutical company, announced today that effective June 27, 2006, the company has received US patent approval for treatment of rheumatoid arthritis by administering Product R (AVR118), a peptide-nucleic acid preparation. Rheumatoid arthritis, a chronic inflammatory illness, is an autoimmune disease in which the immune system attacks normal tissue components as if they were invading pathogens. This illness affects about one percent of the world's population.
"We are excited that the US Patent Office has granted us with this important patent," says Stephen M. Elliston, CEO and President of Advanced Viral Research. "With such a large population affected by rheumatoid arthritis, the commercial prospects for AVR118 may potentially be expanded to include patients suffering from this debilitating disease. This also comes at a time when the treatment options for RA have been limited significantly by the withdrawal of COX II inhibitors from the market."
Advanced Viral Research Corp., based in Yonkers, New York, is a biopharmaceutical firm dedicated to improving patients' lives by researching, developing and bringing to market new and effective therapies for viral and other diseases. ADVR's lead product, AVR118 (formerly known as Product R), represents a complex mixture of peptides, amino acids, nucleosides, nucleotides and nucleic acid bases that possesses, among other things, immunomodulatory activity. We believe it may be employed in the treatment of diseases and conditions such as: Various conditions associated with cancer; cachexia, or body wasting, in patients with acquired immune deficiency syndrome (AIDS), cancer, human immunodeficiency virus, or HIV, including AIDS as a combination therapy; type 2 diabetes; human papilloma virus, or HPV; and rheumatoid arthritis. ADVR is in clinical trials for treatment of cachexia (body wasting) in patients with AIDS.
Note: This news release contains forward-looking statements that involve risks associated with clinical development, regulatory approvals, including application to the FDA, product commercialization and other risks described From time to time in the SEC reports filed by the Company. AVR118 (Product R) is not approved by the U.S. Food and Drug Administration or any comparable Agencies of any other countries. There is no assurance that the Company will be able to secure the financing necessary to continue and/or complete the clinical trials of AVR118 or satisfy certain other conditions relating to clinical trials including obtaining adequate insurance on terms acceptable to the Company or that if completed, clinical trials performed outside the United States will assist the Company in obtaining FDA or other regulatory approval. The Company undertakes no obligation to update or revise the information contained in this announcement whether as a result of new information, future Events or circumstances or otherwise.
For further information regarding Advanced Viral Research Corp., please Visit our website at http://www.adviral.com.
SOURCE: Advanced Viral Research Corp.
Equity Relations, Inc. Richard Brown, 617-314-7379 staff*equityrelations.com
Posts: 106 | Registered: May 2006
| IP: Logged |
Related Quotes Sym. Price Chg. ADVR Trade News 0.073 0.005 Advanced Viral Research (ADVR) Announces Results of Topical Animal Study Indicating AVR 118 Accelerates Wound Healing
August 07, 2006 09:35:24 (ET)
YONKERS, N.Y., Aug 07, 2006 (BUSINESS WIRE) -- Advanced Viral Research Corp. (ADVR, Trade) a bio-pharmaceutical company, announced today that a wound healing study topically applying its pharmaceutical drug AVR 118 to pigs has shown that AVR 118 accelerates the rate at which wounds heal. Although preliminary, these studies provide the rationale for advancing AVR 118 to the human testing stage.
"This study has already generated interest from two major dermatological and wound healing centers in North America and Europe and we intend to move forward with a clinical trial plan," says Stephen M. Elliston, President and CEO of Advanced Viral Research.
"These findings are extremely important because the regenerative properties of the pig model closely parallel those of humans. The wounds treated in this study with AVR 118 healed faster than those treated with a saline control" added Elliston.
Advanced Viral Research Corp is a New York based biopharmaceutical company dedicated to improving patients' lives by researching, developing and bringing to market new and effective therapies for the systematic control of symptoms associated with cancer and other serious diseases. ADVR's lead product, AVR118 represents a new class of complex cytoprotective agents that target among other things, cachexia related disorders. AVR118 has also shown to have topical wound healing properties in animal models.
Various degenerative conditions associated with body wasting (cachexia) such as cancer, HIV-AIDS and chronic inflammation are potential disease targets for AVR118 therapy.
Note: This news release contains forward-looking statements that involve risks associated with clinical development, regulatory approvals, including application to the FDA, product commercialization and other risks described from time to time in the SEC reports filed by the Company. AVR118 (Product R) is not approved by the U.S. Food and Drug Administration or any comparable agencies of any other countries. There is no assurance that the Company will be able to secure the financing necessary to continue and/or complete the clinical trials of AVR118 or satisfy certain other conditions relating to clinical trials including obtaining adequate insurance on terms acceptable to the Company or that if completed, clinical trials performed outside the United States will assist the Company in obtaining FDA or other regulatory approval. The Company undertakes no obligation to update or revise the information contained in this announcement whether as a result of new information, future events or circumstances or otherwise.
For further information regarding Advanced Viral Research Corp., please Visit our website at http://www.adviral.com.
SOURCE: Advanced Viral Research Corp.
Equity Relations, Inc. Richard Brown, 617-314-7379 staff*equityrelations.com Copyright Business Wire 2006
Posts: 106 | Registered: May 2006
| IP: Logged |
posted
Nice, holding mid .07's here well. GSCO has been atop the bid for the past month buying up evrything. He's back at .10 on the ask!
Posts: 410 | Registered: Jan 2006
| IP: Logged |
posted
Bid building here! GSCO just keeps pushing the bid up. .075 ask getting hit here now, gonna close near HOD!
Posts: 410 | Registered: Jan 2006
| IP: Logged |
posted
yep... nice steady climb and the news are good... GSCO at .10 on the ask....Holding on to this one a little longer
Posts: 5120 | Registered: Jun 2004
| IP: Logged |
posted
Definitely some long term possibilities here. Have to wait to see how development and sales go. JMO
Posts: 106 | Registered: May 2006
| IP: Logged |
posted
Looked like some huge buys going through at .07 which I see as decent support. Volume jumped to 416,000 in a minute.
Posts: 410 | Registered: Jan 2006
| IP: Logged |
UBBFriend: Email this page to someone!
Printer-friendly view of this topic
